398 related articles for article (PubMed ID: 26337986)
1. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting.
Thukkani AK; Agrawal K; Prince L; Smoot KJ; Dufour AB; Cho K; Gagnon DR; Sokolovskaya G; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S
J Am Coll Cardiol; 2015 Sep; 66(10):1091-101. PubMed ID: 26337986
[TBL] [Abstract][Full Text] [Related]
2. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
Siddiqi OK; Smoot KJ; Dufour AB; Cho K; Young M; Gagnon DR; Ly S; Temiyasathit S; Faxon DP; Gaziano JM; Kinlay S
Heart; 2015 Oct; 101(19):1569-76. PubMed ID: 26209334
[TBL] [Abstract][Full Text] [Related]
3. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Faxon DP; Lawler E; Young M; Gaziano M; Kinlay S
Circ Cardiovasc Interv; 2012 Jun; 5(3):372-80. PubMed ID: 22668555
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
5. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
[TBL] [Abstract][Full Text] [Related]
7. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
Eisenstein EL; Anstrom KJ; Kong DF; Shaw LK; Tuttle RH; Mark DB; Kramer JM; Harrington RA; Matchar DB; Kandzari DE; Peterson ED; Schulman KA; Califf RM
JAMA; 2007 Jan; 297(2):159-68. PubMed ID: 17148711
[TBL] [Abstract][Full Text] [Related]
8. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Tada T; Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Byrne RA; Kastrati A; Kadota K; Iwabuchi M; Shizuta S; Tazaki J; Shiomi H; Abe M; Ehara N; Mizoguchi T; Mitsuoka H; Inada T; Araki M; Kaburagi S; Taniguchi R; Eizawa H; Nakano A; Suwa S; Takizawa A; Nohara R; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
Circ Cardiovasc Interv; 2012 Jun; 5(3):381-91. PubMed ID: 22619260
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
Brar SS; Kim J; Brar SK; Zadegan R; Ree M; Liu IL; Mansukhani P; Aharonian V; Hyett R; Shen AY
J Am Coll Cardiol; 2008 Jun; 51(23):2220-7. PubMed ID: 18534267
[TBL] [Abstract][Full Text] [Related]
10. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
11. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
[TBL] [Abstract][Full Text] [Related]
12. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
[TBL] [Abstract][Full Text] [Related]
14. Multiple arterial grafting confers survival advantage compared to percutaneous intervention with drug-eluting stents in multivessel coronary artery disease: A propensity score adjusted analysis.
Raja SG; Benedetto U; Ilsley CD; Amrani M;
Int J Cardiol; 2015; 189():153-8. PubMed ID: 25897895
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.
Luo Y; Yu X; Chen F; Du X; He J; Gao Y; Zhang X; Zhang Y; Ren X; Lv S; Ma C
Coron Artery Dis; 2012 Aug; 23(5):322-9. PubMed ID: 22750912
[TBL] [Abstract][Full Text] [Related]
16. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
El Ghannudi S; Ohlmann P; Jesel L; Radulescu B; El Adraa E; Crimizade U; Wiesel ML; Gachet C; Morel O
Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
[TBL] [Abstract][Full Text] [Related]
17. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
[TBL] [Abstract][Full Text] [Related]
18. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
19. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients.
Minha S; Bental T; Assali A; Vaknin-Assa H; Lev EI; Rechavia E; Battler A; Kornowski R
Catheter Cardiovasc Interv; 2011 Nov; 78(5):710-7. PubMed ID: 21805561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
